GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Operating Margin %

Giant Biogene Holding Co (HKSE:02367) Operating Margin % : 49.14% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Giant Biogene Holding Co's Operating Income for the six months ended in Dec. 2023 was HK$1,031 Mil. Giant Biogene Holding Co's Revenue for the six months ended in Dec. 2023 was HK$2,098 Mil. Therefore, Giant Biogene Holding Co's Operating Margin % for the quarter that ended in Dec. 2023 was 49.14%.

The historical rank and industry rank for Giant Biogene Holding Co's Operating Margin % or its related term are showing as below:

HKSE:02367' s Operating Margin % Range Over the Past 10 Years
Min: 47.24   Med: 60.01   Max: 70.83
Current: 47.24


HKSE:02367's Operating Margin % is ranked better than
99.03% of 1859 companies
in the Consumer Packaged Goods industry
Industry Median: 5.15 vs HKSE:02367: 47.24

Giant Biogene Holding Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Giant Biogene Holding Co's Operating Income for the six months ended in Dec. 2023 was HK$1,031 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,821 Mil.


Giant Biogene Holding Co Operating Margin % Historical Data

The historical data trend for Giant Biogene Holding Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Operating Margin % Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
70.83 68.16 60.01 49.85 47.24

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial - 51.44 48.71 44.97 49.14

Competitive Comparison of Giant Biogene Holding Co's Operating Margin %

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Giant Biogene Holding Co's Operating Margin % Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Operating Margin % falls into.



Giant Biogene Holding Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Giant Biogene Holding Co's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1821.003 / 3854.633
=47.24 %

Giant Biogene Holding Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1031.215 / 2098.355
=49.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Giant Biogene Holding Co  (HKSE:02367) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Giant Biogene Holding Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co (HKSE:02367) Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Yan Jianya 2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited 2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines